RXRX - Recursion Pharmaceuticals Inc - Ordinary Shares - Class A
IEX Last Trade
7.27
-0.140 -1.926%
Share volume: 3,550,212
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$7.41
-0.14
-1.89%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-09 | 2022-11-08 | 2023-02-27 | 2023-05-08 | 2023-08-08 | 2023-11-09 | 2024-02-29 | 2024-05-09 | |
| Assets | |||||||||
| Total Assets | 672.515 M | 611.533 M | 701.288 M | 627.366 M | 666.699 M | 630.825 M | 653.699 M | 557.847 M | |
| Current Assets | 545.996 M | 481.618 M | 569.814 M | 492.125 M | 431.020 M | 410.522 M | 438.137 M | 343.615 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 16.979 M | 13.247 M | 15.869 M | 15.612 M | 18.774 M | 17.780 M | 40.247 M | 41.495 M | |
| Short Term Investments | 78.540 M | 13.247 M | 15.869 M | 15.612 M | 18.774 M | 17.780 M | 40.247 M | 41.495 M | |
| Total Receivables | 11.680 M | 11.635 M | 2.753 M | 2.057 M | 3.051 M | 3.164 M | 3.094 M | 2.599 M | |
| Current Cash | 453.875 M | 454.646 M | 549.912 M | 473.145 M | 405.870 M | 387.322 M | 391.565 M | 296.326 M | |
| Total Non-current Assets | 126.519 M | 129.915 M | 131.474 M | 135.241 M | 235.679 M | 220.303 M | 215.562 M | 214.232 M | |
| Property Plant Equipment | 81.508 M | 85.777 M | 88.192 M | 90.004 M | 89.768 M | 86.248 M | 86.510 M | 86.716 M | |
| Other Assets | 34.643 M | 33.726 M | 33.255 M | 35.198 M | 35.009 M | 34.217 M | 33.924 M | 35.755 M | |
| Intangible Assets | 1.233 M | 1.457 M | 1.306 M | 1.318 M | 42.757 M | 39.459 M | 36.443 M | 33.076 M | |
| Goodwill | 801.000 K | 801.000 K | 801.000 K | 801.000 K | 60.516 M | 52.750 M | 52.056 M | 52.056 M | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 672.515 M | 611.533 M | 701.288 M | 627.366 M | 666.699 M | 630.825 M | 653.699 M | 557.847 M | |
| Total liabilities | 234.936 M | 223.499 M | 215.482 M | 197.191 M | 197.736 M | 192.858 M | 190.263 M | 156.696 M | |
| Total current liabilities | 96.653 M | 83.036 M | 100.265 M | 92.150 M | 113.959 M | 94.118 M | 93.171 M | 73.920 M | |
| Accounts Payable | 3.176 M | 3.890 M | 4.586 M | 4.247 M | 2.086 M | 4.265 M | 3.953 M | 5.115 M | |
| Other liabilities | 89.934 M | 93.909 M | 70.261 M | 57.091 M | 32.436 M | 51.383 M | 51.238 M | 37.391 M | |
| Current long term debt | 5.335 M | 5.636 M | 6.049 M | 5.101 M | 5.895 M | 6.050 M | 6.157 M | 6.117 M | |
| Long term debt | 48.349 M | 46.554 M | 44.956 M | 47.950 M | 47.005 M | 45.426 M | 44.515 M | 44.857 M | |
| Other liabilities | 89.934 M | 93.909 M | 70.261 M | 57.091 M | 32.436 M | 51.383 M | 51.238 M | 37.391 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 437.579 M | 388.034 M | 485.806 M | 430.175 M | 468.963 M | 437.967 M | 463.436 M | 401.151 M | |
| Common stock | 172.212 M | 173.436 M | 185.811 M | 191.618 M | 201.415 M | 214.327 M | 224.054 M | 236.019 M | |
| Retained earnings | -521.619 M | -582.064 M | -639.556 M | -704.883 M | -781.609 M | -874.626 M | -967.622 M | -1.059 B |